According to the Gooznews…

The committee advising the Health and Human Services department on how it should spend its portion of the $1.1 billion for comparative effectiveness research included in the stimulus package has listed cost of care as a major factor to consider when determining what research ought to get done. That recommendation rejects testimony from industry and some patient advocacy groups (mostly industry-funded), who specifically called for eliminating cost as a factor when considering which technologies to evaluate.

Here’s the first of HHS’ five proposed criteria:

1. Potential Impact (based on prevalence of condition, burden of disease, variability in outcomes, and costs of care)

Be sure to submit feedback prior to June 10, 2009. HHS Feedback Form

Tagged with:

Filed under: HHS

Like this post? Subscribe to my RSS feed and get loads more!